GEMoaB Monoconals GmbH develops innovative antibody-based therapeutics against infectious diseases and tumors.

Based on novel immunotherapeutic concepts GEMoaB developed an innovative approach using a modular system of bi-specific antibodies. Owing to this modular system, development times of new therapeutic drugs are considerably shortened. Thus, our technology enables the rapid generation of novel, efficient substances with limited side-effects.

Our motivation and the focus of our research is to benefit patients suffering from a wide range of diseases. Our strength lies in the close cooperation between academic scientists, medical and pharmaceutical experts working hand in hand towards our goal.

GEMoaB – the fastest way to a novel bi-specific antibody!